Giannicola Genovese

List of Publications by Year in Descending Order

46 papers	8,023 citations	27 h-index	54 g-index
54 ext. papers	10,101 ext. citations	17.1 avg, IF	4.6 L-index

#	Paper	IF	Citations
46	Multi-site desmoplastic small round cell tumors are genetically related and immune-cold.. *Npj Precision Oncology*, **2022**, 6, 21	9.8	1
45	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. *European Urology Oncology*, **2021**,	6.7	3
44	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. *Cancers*, **2021**, 13,	6.6	3
43	TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?. *Expert Opinion on Therapeutic Targets*, **2021**, 25, 141-151	6.4	6
42	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. *Cancers*, **2021**, 13,	6.6	2
41	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. *Cancer Discovery*, **2021**, 11, 2904-2923	24.4	2
40	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. *Nature Communications*, **2021**, 12, 4626	17.4	4
39	Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. *Cancer Research*, **2021**, 81, 332-343	10.1	7
38	Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesnt, and What the Future Holds. *Clinical Genitourinary Cancer*, **2021**, 19, 103-116	3.3	13
37	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. *Nature Communications*, **2021**, 12, 808	17.4	26
36	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. *Gastroenterology*, **2021**, 161, 196-210	13.3	5
35	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. *Science*, **2021**, 373, eabj0486	33.3	14
34	Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. *Clinical Genitourinary Cancer*, **2021**,	3.3	1
33	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. *Cancers*, **2020**, 12,	6.6	2
32	Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. *Cancer Discovery*, **2020**, 10, 608-625	24.4	52
31	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. *Cancer Cell*, **2020**, 37, 720-734.e13	24.3	32
30	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. *Cancer Treatment and Research Communications*, **2020**, 23, 100166	2	14

29	Leukotrienes, a potential target for Covid-19. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2020**, 161, 102174	2.8	5
28	Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. *Molecular and Cellular Oncology*, **2020**, 7, 1777060	1.2	2
27	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. *Cell Reports*, **2019**, 26, 1518-1532.e9	10.6	36
26	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. *Cancer Cell*, **2019**, 35, 204-220.e9	24.3	32
25	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, 1-6	3.3	28
24	Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2019**, 13, 659-668	1.5	32
23	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. *Nature*, **2017**, 542, 119-123	50.4	145
22	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. *Nature*, **2017**, 542, 362-366	50.4	70
21	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. *Cell Reports*, **2017**, 18, 2780-2794	10.6	247
20	In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. *Cell Reports*, **2016**, 16, 133-147	10.6	77
19	Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. *Cell Reports*, **2016**, 14, 1555-1566	10.6	175
18	Genomic Classification of Cutaneous Melanoma. *Cell*, **2015**, 161, 1681-96	56.2	1807
17	Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. *Cancer Cell*, **2015**, 27, 644-57	24.3	68
16	Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. *Cancer Research*, **2015**, 75, 1091-101	10.1	53
15	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. *Nature*, **2014**, 514, 628-32	50.4	727
14	The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. *Cancer Research*, **2014**, 74, 4845-4852	10.1	111
13	The Somatic Genomic Landscape of Glioblastoma. *Cell*, **2014**, 157, 753	56.2	29
12	The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77	56.2	2900

11	microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-□signaling in glioblastoma. *Cancer Discovery*, **2012**, 2, 736-49	24.4	90
10	Passenger deletions generate therapeutic vulnerabilities in cancer. *Nature*, **2012**, 488, 337-42	50.4	224
9	Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. *Journal of Experimental and Clinical Cancer Research*, **2012**, 31, 71	12.8	42
8	Emerging insights into the molecular and cellular basis of glioblastoma. *Genes and Development*, **2012**, 26, 756-84	12.6	388
7	The tumor suppressor HINT1 regulates MITF and □catenin transcriptional activity in melanoma cells. *Cell Cycle*, **2012**, 11, 2206-15	4.7	33
6	Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. *Nature Medicine*, **2012**, 18, 1503-10	50.5	270
5	Loss of nuclear p27(kip1) and □dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma. *Cancer Science*, **2010**, 101, 2080-6	6.9	18
4	Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. *Journal of Cellular Physiology*, **2010**, 224, 234-41	7	31
3	Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter. *American Journal of Physiology - Cell Physiology*, **2009**, 297, C1113-23	5.4	20
2	Actein inhibits the Na+-K+-ATPase and enhances the growth inhibitory effect of digitoxin on human breast cancer cells. *Biochemical and Biophysical Research Communications*, **2008**, 375, 608-13	3.4	37
1	Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. *Cancer Biology and Therapy*, **2007**, 6, 1840-6	4.6	25